WCN 2026 28 - 31 March 2026

Mechanistic kidney effects of semaglutide by baseline SGLT2i use in type 2 diabetes: a post-hoc analysis of the REMODEL trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Chronic Kidney Disease
Congress short oral presentation
GLP-1 RA
Semaglutide
PHASE 3 (RCT)